dual glp 1 glucagon receptor agonists LY3437943, a novel triple glucagon, GIP, and GLP-1 agonist for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism The dual agonist action of
Description
(2024) 3:e244369
It activates the same GLP-1 pathway semaglutide uses, but it also targets glucose-dependent insulinotropic polypeptide (GIP) receptors
doi: 10.1007/s11910-025-01423-9
doi: 10.3390/MEDICINA60010050 102 CannarellaRCalogeroAECondorelliRAGrecoEAAversaALa VigneraS
GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: State of the art
tirzepatide is contraindicated in individuals with personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia type 2 syndromes (54, 61)
